Van Swearingen, A. E. D., Sambade, M. J., Siegel, M. B., Sud, S., McNeill, R. S., Bevill, S. M., . . . Anders, C. K. (2017). Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro Oncol.
Chicago-tyylinen lähdeviittausVan Swearingen, Amanda E D., et al. "Combined Kinase Inhibitors of MEK1/2 and Either PI3K or PDGFR Are Efficacious in Intracranial Triple-negative Breast Cancer." Neuro Oncol 2017.
MLA-viiteVan Swearingen, Amanda E D., et al. "Combined Kinase Inhibitors of MEK1/2 and Either PI3K or PDGFR Are Efficacious in Intracranial Triple-negative Breast Cancer." Neuro Oncol 2017.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.